Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.37 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.37 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5552498 | 1.00 | MEN1 (0.45) | MEN1ALDH1A1MAPTKMT2AGPR119 | |
| SCHEMBL30616349 | 0.86 | MEN1 (0.51) | MEN1ALDH1A1MAPTKMT2AGPR119 | |
| SCHEMBL28965083 | 0.85 | MEN1 (0.44) | MEN1ALDH1A1MAPTKMT2ANR1H2 | |
| SCHEMBL13442980 | 0.82 | NR1H2 (0.44) | MEN1ALDH1A1MAPTKMT2AGPR119 | |
| SCHEMBL17477191 | 0.82 | NR1H2 (0.44) | MEN1ALDH1A1MAPTKMT2AGPR119 | |
| SCHEMBL17477192 | 0.82 | NR1H2 (0.44) | MEN1ALDH1A1MAPTKMT2AGPR119 | |
| SCHEMBL5552520 | 0.81 | NR1H2 (0.47) | MEN1ALDH1A1MAPTKMT2AGPR119 | |
| SCHEMBL23235715 | 0.80 | SLC6A9 (0.44) | MEN1ALDH1A1MAPTKMT2AGPR119 | |
| SCHEMBL15217058 | 0.80 | SETD7 (0.42) | MEN1ALDH1A1MAPTKMT2AGPR119 | |
| SCHEMBL22346776 | 0.80 | NR1H2 (0.46) | MEN1ALDH1A1MAPTKMT2AGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559506-B2 | Indazole based compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20240360152-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-10-31 | — | — | US | disclosed |
| US-11981683-B2 | Indazole based compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4308557-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-117321046-A | Indazole-based compounds and related methods of use | 阿维纳斯企业公司 | 2023-12-29 | — | — | CN | disclosed |
| US-20230097358-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2023-03-30 | — | — | US | disclosed |
| WO-2022198112-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360152-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | MEN1 2327/4885ALDH1A1 3531/4885MAPT 403/4885 |
| US-12559506-B2 | Indazole based compounds and associated methods of use | LRRK2, CRBN, CLK2 | MEN1 1946/4885ALDH1A1 3579/4885MAPT 187/4885 |
| US-11981683-B2 | Indazole based compounds and associated methods of use | LRRK2, CRBN, MDM2 | MEN1 2327/4885ALDH1A1 3531/4885MAPT 403/4885 |
| US-20230097358-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | MEN1 2327/4885ALDH1A1 3531/4885MAPT 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.